"Performance" BIOSTAR PHARM-B's annual loss narrowed to 131 million RMB, no dividend declared
BIOSTAR PHARM-B (02563.HK) announced its 2025 annual results, with revenue of RMB 33.36 million, a year-on-year decrease of 53.6%. Losses narrowed to RMB 131 million, compared to a loss of RMB 144 million in the same period last year; loss per share is RMB 0.36. No dividend is declared
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments